오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - amitriptyline hydrochloride, quantity: 50 mg - tablet - excipient ingredients: magnesium stearate; purified talc; microcrystalline cellulose; lactose monohydrate; crospovidone; maize starch; hypromellose; titanium dioxide; sunset yellow fcf aluminium lake; colloidal anhydrous silica; macrogol 6000; indigo carmine aluminium lake - for the treatment of major depression. amitriptyline 50 mg tablets are indicated only for the maintenance treatment of major depression ,nocturnal enuresis where organic pathology has been excluded.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - amitriptyline hydrochloride, quantity: 10 mg - tablet - excipient ingredients: magnesium stearate; colloidal anhydrous silica; hypromellose; microcrystalline cellulose; crospovidone; maize starch; purified talc; lactose monohydrate; brilliant blue fcf aluminium lake; titanium dioxide; macrogol 6000 - for the treatment of major depression. amitriptyline 50 mg tablets are indicated only for the maintenance treatment of major depression ,nocturnal enuresis where organic pathology has been excluded.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - amitriptyline hydrochloride, quantity: 50 mg - tablet, film coated - excipient ingredients: sodium starch glycollate; pregelatinised maize starch; colloidal anhydrous silica; lactose monohydrate; magnesium stearate; purified talc; disodium edetate; microcrystalline cellulose; titanium dioxide; hypromellose; iron oxide yellow; iron oxide red; macrogol 4000; iron oxide black - amitriptyline alphapharm 50mg tablets are indicated only for the maintenance treatment of major depression. (see precautions). nocturnal enuresis where organic pathology has been excluded.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

micro labs pty ltd - hydrochlorothiazide, quantity: 12.5 mg; irbesartan, quantity: 300 mg - tablet, film coated - excipient ingredients: povidone; colloidal anhydrous silica; mannitol; iron oxide red; iron oxide yellow; sodium starch glycollate type b; magnesium stearate; polysorbate 80; hypromellose; titanium dioxide; carnauba wax; macrogol 3350 - indicated for the treatment of hypertension. treatment should not be initiated with this fixed-dose combination.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

micro labs pty ltd - hydrochlorothiazide, quantity: 25 mg; irbesartan, quantity: 300 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; sodium starch glycollate type b; polysorbate 80; mannitol; hypromellose; magnesium stearate; povidone; titanium dioxide; iron oxide red; macrogol 3350; carnauba wax; iron oxide black - indicated for the treatment of hypertension. treatment should not be initiated with this fixed-dose combination.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

micro labs pty ltd - irbesartan, quantity: 150 mg; hydrochlorothiazide, quantity: 12.5 mg - tablet, film coated - excipient ingredients: polysorbate 80; sodium starch glycollate type b; colloidal anhydrous silica; mannitol; hypromellose; povidone; magnesium stearate; titanium dioxide; iron oxide yellow; iron oxide red; carnauba wax; macrogol 3350 - indicated for the treatment of hypertension. treatment should not be initiated with this fixed-dose combination.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

micro labs pty ltd - potassium clavulanate, quantity: 151.917 mg; amoxicillin trihydrate, quantity: 1004.31 mg - tablet, film coated - excipient ingredients: dichloromethane; isopropyl alcohol; microcrystalline cellulose; sodium starch glycollate; magnesium stearate; colloidal anhydrous silica; titanium dioxide; hypromellose; macrogol 400 - amoxyclav mlabs 875/125 tablets are indicated for short-term treatment of bacterial infections at the following sites when caused by sensitive organisms (refer to microbiology):,urinary tract infections (complicated and uncomplicated),lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis,upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis.,skin and skin structure infection.,appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to amoxicillin and clavulanic acid tablets. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed above, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate. the treatment of mixed infections caused by amoxicillin susceptible organisms and beta-lactamase producing organisms susceptible to amoxicillin and clavulanic acid tablets preparations should not require the addition of another antibiotic due to the amoxicillin content of these products.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

micro labs pty ltd - potassium clavulanate, quantity: 151.917 mg; amoxicillin trihydrate, quantity: 573.892 mg - tablet, film coated - excipient ingredients: isopropyl alcohol; colloidal anhydrous silica; magnesium stearate; sodium starch glycollate; dichloromethane; microcrystalline cellulose; titanium dioxide; hypromellose; macrogol 400 - amoxyclav mlabs 500/125 tablets are indicated for short-term treatment of bacterial infections at the following sites when caused by sensitive organisms (refer to microbiology):,urinary tract infections (complicated and uncomplicated),lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis,upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis.,skin and skin structure infection.,appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to amoxicillin and clavulanic acid tablets. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed above, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate. the treatment of mixed infections caused by amoxicillin susceptible organisms and beta-lactamase producing organisms susceptible to amoxicillin and clavulanic acid tablets preparations should not require the addition of another antibiotic due to the amoxicillin content of these products.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

micro labs pty ltd - gabapentin, quantity: 100 mg - capsule, hard - excipient ingredients: maize starch; purified talc; titanium dioxide; purified water; gelatin; sodium lauryl sulfate - gabapentin is indicated for the treatment of partial seizures, including secondarily generalised tonic-clonic seizures, initially as add-on therapy in adults and children age 3 years and above who have not achieved adequate control with standard anti-epileptic drugs.,gabapentin is indicated for the treatment of neuropathic pain.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

micro labs pty ltd - gabapentin, quantity: 300 mg - capsule, hard - excipient ingredients: purified talc; maize starch; titanium dioxide; purified water; iron oxide yellow; gelatin; sodium lauryl sulfate - gabapentin is indicated for the treatment of partial seizures, including secondarily generalised tonic-clonic seizures, initially as add-on therapy in adults and children age 3 years and above who have not achieved adequate control with standard anti-epileptic drugs.,gabapentin is indicated for the treatment of neuropathic pain.